Displaying drugs 11401 - 11425 of 11783 in total
Firtecan pegol
Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).
Investigational
Matched Description: … Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients …
Edasalonexent
Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).
Investigational
Matched Description: … Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of …
Nemolizumab
Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
Investigational
Matched Description: … Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study …
Flutriciclamide F-18
Flutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques).
Investigational
Matched Description: … Flutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation …
Cenersen
Cenersen is under investigation in clinical trial NCT02243124 (A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)).
Investigational
Matched Description: … Cenersen is under investigation in clinical trial NCT02243124 (A Study of Aezea® (Cenersen) in Transfusion …
Valomaciclovir stearate
Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster).
Investigational
Matched Description: … Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB …
Fisogatinib
Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib(blu-554) in Subjects With Hepatocellular Carcinoma).
Investigational
Matched Description: … Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib( …
TPIV 200
TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).
Investigational
Matched Description: … TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage …
DCN-tCRK
DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal vascular homing peptide tCRK.
Investigational
Matched Description: … DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal …
Daledalin
Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.
Experimental
Matched Description: … Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. …
Talacotuzumab
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute …
Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting …
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo …
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected …
ZYCOV-D
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid ... Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a …
4-Methyl-2,5-dimethoxyamphetamine
A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.
Experimental
Illicit
Matched Description: … A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and …
Gemcabene
Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).
Investigational
Matched Description: … Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides …
GW 597599
GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced vomiting; functional dyspepsia; depression and anxiety.
Investigational
Matched Description: … GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced …
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Matched Description: … ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment …
Styphnolobium japonicum flower bud
Styphnolobium japonicum flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Styphnolobium japonicum flower bud is a plant/plant extract used in some OTC (over-the-counter) products …
Elismetrep
Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects).
Investigational
Matched Description: … Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability …
SLV-334
SLV-334 is under investigation in clinical trial NCT00735085 (A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.).
Investigational
Matched Description: … SLV-334 is under investigation in clinical trial NCT00735085 (A Phase 2a Dose Escalation Study With SLV334 …
Displaying drugs 11401 - 11425 of 11783 in total